Clinical evidence as a growth asset, not a compliance cost

Evidence unlocks specific buyers at specific stages, plan for that

A pilot case study with a single site is enough to open a conversation with an early adopter health system. It is not enough for a payer to consider reimbursement, and it is nowhere near enough for a large integrated delivery network's value analysis committee, which typically wants peer-reviewed, ideally multi-site, evidence before it will approve spend. Map your evidence roadmap against your buyer roadmap explicitly: what does each tier of buyer need to see before they will move, and in what order will you generate it.

This reframes evidence generation from a single big study you cannot afford yet into a sequence: an internal outcomes analysis, then a single-site case study, then a multi-site retrospective, then a prospective study or registry, each one unlocking the next tier of buyer and, not coincidentally, the next round of funding.

Design studies that answer the question your buyer actually asks

A common and costly mistake is generating evidence that satisfies an academic reviewer but does not answer the question a hospital CFO or a payer medical director actually asks, which is usually about cost, utilisation or a specific clinical outcome tied to reimbursement, not a generic efficacy measure. Before designing a study, interview three to five target buyers and ask exactly what evidence would move a purchase decision. Design backwards from that answer.

Health economics and outcomes research, commonly known as HEOR, is the discipline built for exactly this translation between clinical outcome and buyer decision. Even a lightweight HEOR input at study design stage, before you have collected a single data point, will save you from publishing a technically correct study that nobody in procurement can use.

Turn one study into a year of growth assets

A single well-designed study is not one marketing asset, it is a dozen. The peer-reviewed publication itself matters for credibility with clinicians, but the growth value comes from what you build around it: a plain-language summary for buyers who will never read the journal article, a webinar with the lead investigator, a KOL speaking programme built around the findings, sales enablement one-pagers by buyer persona, and a PR angle timed to publication.

Sequence these deliberately rather than releasing everything at once. Peer-reviewed publication first (this is what gives everything else credibility), then KOL amplification, then buyer-facing translation, then broader press. Releasing a buyer-facing claim ahead of publication undermines the credibility the study was meant to build.

• Peer-reviewed publication, the credibility anchor for everything else
• KOL commentary and speaking slots at the relevant clinical conference
• Plain-language buyer summary mapped to the specific procurement question it answers
• Sales enablement one-pagers segmented by buyer type: clinical, financial, payer
• Timed press and content amplification, sequenced after publication, not before

KOL strategy is a growth channel, treat it like one

Key opinion leader relationships are usually owned by clinical or medical affairs teams and treated as separate from growth marketing. That separation costs companies real pipeline. A well-chosen KOL, engaged early in study design rather than recruited after the fact to promote a finished study, brings credibility that no amount of paid marketing can buy, particularly with provider buyers who discount vendor claims by default and weight peer recommendation heavily.

Build a KOL engagement plan with the same rigour as a channel plan: identify the two or three KOLs whose endorsement would move your specific target buyers, involve them authentically in evidence generation or advisory work, disclose the relationship transparently, and give them a genuine platform rather than a scripted quote.